Primary pulmonary adenoid cystic carcinoma: A clinicopathological study of 64 patients
ConclusionPrognostic analysis revealed that age, tumor size, lymph node metastasis status, margin status, and choice of treatment modality significantly influenced the patients' prognosis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 27, 2023 Category: Cancer & Oncology Authors: Xiang Tan,
Tao Xu,
Wang Shen,
Cheng Ai,
Weilin Zhang,
Xiaojun Tang,
Feng Luo,
Qinghua Zhou Tags: ORIGINAL ARTICLE Source Type: research
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies
ConclusionOur findings indicate that fluoropyrimidine can be an immunologically optimal partner of ICIs through the induction of ICD for thoracic malignancies. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 26, 2023 Category: Cancer & Oncology Authors: Hiroyuki Kozai,
Hirokazu Ogino,
Atsushi Mitsuhashi,
Na Thi Nguyen,
Yuki Tsukazaki,
Yohei Yabuki,
Ryohiko Ozaki,
Hiroto Yoneda,
Seidai Sato,
Masaki Hanibuchi,
Tsutomu Shinohara,
Hiroshi Nokihara,
Yasuhiko Nishioka Tags: ORIGINAL ARTICLE Source Type: research
A case of primary lung adenocarcinoma mimicking metastatic papillary thyroid carcinoma
We report a case of primary lung adenocarcinoma arising in the lung with multiple metastatic nodules of the follicular variant of papillary thyroid carcinoma (PTC). This case highlights the need for comprehensive analyses including morphology, immunohistochemistry and genetic analyses to differentiate the primary lung adenocarcinoma from the metastatic PTCs. AbstractA 61-year-old woman, who had a history of total thyroidectomy for follicular variant of papillary thyroid carcinoma (PTC), visited our hospital for assessment of an enlarging nodule which appeared in the lung with multiple metastatic lesions of PTC which had be...
Source: Thoracic Cancer - December 23, 2023 Category: Cancer & Oncology Authors: Akira Tanaka,
Riki Okita,
Takushi Morishige,
Masanori Okada,
Hidetoshi Inokawa,
Katsutoshi Hirazawa,
Kaori Kameyama,
Akihiko Ikeda,
Eiji Ikeda Tags: CASE REPORT Source Type: research
TPI1 promotes MAPK/ERK ‐induced EMT, cell migration and invasion in lung adenocarcinoma
ConclusionTPI1 promotes LUAD metastasis by activating the MAPK/ERK signaling pathway. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 22, 2023 Category: Cancer & Oncology Authors: Yu Li,
Bin Pan,
Feiyang Zhang,
Xinyu Jia,
Xinyu Zhu,
Xin Tong,
Jun Zhao,
Chang Li Tags: ORIGINAL ARTICLE Source Type: research
Insight into the significance of CD8+ tumor ‐infiltrating lymphocytes in squamous cell lung cancer
ConclusionOur study provided partial but important information on the significance of CD8 + TILs in SQ-LC. To use CD8 + TILs as biomarkers, a better understanding of CD8 + TILs as well as other important components in the tumor microenvironment and the inflammatory phenotypes they form may be needed. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 21, 2023 Category: Cancer & Oncology Authors: Kazu Shiomi,
Masaaki Ichinoe,
Ai Ushiwata,
Koji Eshima,
Ryo Nagashio,
Shoko Hayashi,
Dai Sonoda,
Yasuto Kondo,
Raito Maruyama,
Masashi Mikubo,
Yoshiki Murakumo,
Yukitoshi Satoh Tags: ORIGINAL ARTICLE Source Type: research
Disruption of LPA ‐LPAR1 pathway results in lung tumor growth inhibition by downregulating B7‐H3 expression in fibroblasts
ConclusionThe present study provided new insights for roles of LPA in CAFs, which could lead to the development of innovative therapies targeting CAFs in the TME. It is also reasonable to postulate a combinatory approach to treat malignant fibrous tumors (such as NSCLC) with LPAR1 antagonists and B7-H3 targeting therapies. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 21, 2023 Category: Cancer & Oncology Authors: Fanyi Meng,
Zhiyue Yin,
Feifei Lu,
Weipeng Wang,
Hongjian Zhang Tags: ORIGINAL ARTICLE Source Type: research
Issue Information
(Source: Thoracic Cancer)
Source: Thoracic Cancer - December 21, 2023 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research
Correction to “Epiplakin1 promotes the progression of esophageal squamous cell carcinoma by activating the PI3K‐AKT signaling pathway”
(Source: Thoracic Cancer)
Source: Thoracic Cancer - December 21, 2023 Category: Cancer & Oncology Tags: CORRECTION Source Type: research
Prognostic, immunity, stemness, and anticancer drug sensitivity characterization of pyroptosis related genes in non ‐small cell lung cancer
ConclusionOur study provided valuable insights into the critical role of PRGs in TME modulation, tumor stemness, and anticancer drug sensitivity across diverse cancers. Our findings illuminate the intricate relationship between pyroptosis and the TME, offering new perspectives for enhancing NSCLC treatment and prognosis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 20, 2023 Category: Cancer & Oncology Authors: Cong Xu,
Hongming Ma,
Jiawen Chen,
Xincheng Li,
Zhina Wang,
Bin Hu,
Nan Zhang,
Fanjie Meng Tags: ORIGINAL ARTICLE Source Type: research
Value of adjuvant chemotherapy for patients with pT2N0M0 non ‐small cell lung cancer receiving radical resection
ConclusionACT was valuable for patients with pathological stage IIA (pT2bN0M0) and patients with radiological pure-solid LUAD of pathological stage IB. A combination of radiological features and pathological subtypes could be helpful when selecting patients with pT2N0M0 NSCLCs for ACT. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 15, 2023 Category: Cancer & Oncology Authors: Shiqi Chen,
Siqian Yang,
Yue Zhao,
Yang Zhang,
Qingyuan Huang,
Haoxuan Wu,
Hong Hu,
Yihua Sun,
Yawei Zhang,
Jiaqing Xiang,
Ting Ye,
Haiquan Chen Tags: ORIGINAL ARTICLE Source Type: research
IgG4 ‐related retroperitoneal fibrosis induced by nivolumab and ipilimumab in a patient with non‐small cell lung cancer: A case report
This study reports the first case of IgG4-related retroperitoneal fibrosis after the administration of chemotherapy with nivolumab and ipilimumab (NI therapy). An 80-year-old man developed lower abdominal pain eight months after NI therapy was initiated. Although the primary lesion maintained its reduced size on computed tomography, there was an increase in the soft tissue shadows intensity around the abdominal aorta, bladder, and seminal vesicles, suggesting retroperitoneal fibrosis. Blood tests showed elevated IgG4 levels. Computed tomography-guided biopsy of the retroperitoneum showed B cell-dominant lymphocyte infiltra...
Source: Thoracic Cancer - December 15, 2023 Category: Cancer & Oncology Authors: Masashi Nishimura,
Yoshifumi Kimizuka,
Takunori Ogawa,
Motohiro Tsuchiya,
Yoshiki Kato,
Akira Matsukida,
Shunya Igarashi,
Koki Ito,
Yusuke Serizawa,
Tomomi Tanigaki,
Yuji Fujikura,
Yuka Katsurada,
Sho Ogata,
Akihiko Kawana Tags: CASE REPORT Source Type: research
Issue Information
(Source: Thoracic Cancer)
Source: Thoracic Cancer - December 14, 2023 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research
Different effects of crizotinib treatment in two non ‐small cell lung cancer patients with SDC4::ROS1 fusion variants
This study aimed to clarify the clinicopathological differences between twoSDC4::ROS1 positive NSCLC cases who had different responses to crizotinib. Cytology and pathology samples from two NSCLC cases withSDC4::ROS1 who were diagnosed and treated with crizotinib at Nihon University Itabashi Hospital were obtained. Case 1 has been well-controlled with crizotinib for over 5 years, but case 2 was worse and overall survival was 19 months. Sequencing analysis ofROS1 fusion genes was performed by reverse-transcription-PCR and Sanger's sequencing methods. In addition, thyroid transcription factor (TTF)-1, ROS-1, Ki67, and p...
Source: Thoracic Cancer - December 14, 2023 Category: Cancer & Oncology Authors: Yuta Ohishi,
Yoko Nakanishi,
Yukari Hirotani,
Atsuko Suzuki,
Tomoyuki Tanino,
Haruna Nishimaki ‐Watanabe,
Hiroko Kobayashi,
Fumi Nozaki,
Sumie Ohni,
Xiaoyan Tang,
Kentaro Hayashi,
Yoshiko Nakagawa,
Tetsuo Shimizu,
Ichiro Tsujino,
Noriaki T Tags: BRIEF REPORT Source Type: research
Advances in new targets for immunotherapy of small cell lung cancer
Immune checkpoint inhibitors have altered the treatment paradigm of small cell lung cancer (SCLC). However, the current immunotherapies, such as programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), brought limited benefits to survival. It is urgent to develop new targets or immunotherapy drugs. This review focuses on multiple new targets of immunotherapy investigated in the field of SCLC, including delta-like ligand 3 (DLL3), T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif structural domains (TIGIT), lymphocyte activation gene-3 ...
Source: Thoracic Cancer - December 14, 2023 Category: Cancer & Oncology Authors: Zitong Zheng,
Juanjuan Liu,
Junling Ma,
Runting Kang,
Zhen Liu,
Jiangyong Yu Tags: REVIEW Source Type: research
Tumor ‐related exosomal circ_0001715 promotes lung adenocarcinoma cell proliferation and metastasis via enhancing M2 macrophage polarization by regulating triggering receptor expressed on myeloid cells‐2
ConclusionExosomal circ_0001715 led to LUAD cell proliferation and metastasis by promoting M2 macrophage polarization via the miR-205-5p/TREM2 axis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 13, 2023 Category: Cancer & Oncology Authors: Mengjun Chen,
Chengzhang Cao,
Jun Ma Tags: ORIGINAL ARTICLE Source Type: research
